Tuesday, 17 February 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 17 February 2026
News

Nice work, CEO wins 30% pay rise

 Posted 16 February 2026 PM

There's been a nice pay bump for Novartis CEO Vas Narasimhan whose compensation has soared by 30 per cent to reach AU$45 million (24.9 million Swiss francs) after the company exceeded its long-term financial targets.

The main driver of the pay rise was a handsome payout tied to Novartis' long-term performance plan with the company's flagship brands Entresto, Kisqali and Kesimpta achieving sales well above expectations.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (4)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.